BioHarvest Sciences Inc.
BioHarvest Sciences Inc. is a biotechnology company focused on Botanical Synthesis, a proprietary platform used to produce plant-based compounds without growing the underlying plant. Its core business centers on developing and commercializing science-based nutraceutical, health, wellness, pharmaceutical, and cosmeceutical solutions, alongside contract development and manufacturing services for third-party partners. The company’s product portfolio includes consumer wellness offerings such as VINIA, a red grape cell supplement, and it also works on plant-derived ingredients for foods, beverages, and specialty applications. BioHarvest Sciences Inc. serves markets spanning dietary supplements, functional foods, health ingredients, and advanced botanical molecules, positioning itself at the intersection of biotechnology and plant-based product innovation. Headquartered in Vancouver, Canada, the company operates with activities in Israel and the United States.
$1.85
+$0.15 (+8.82%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-16.16% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 37.0% YoY with margins expanding 11.6pp.
Negative free cash flow of -$10M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$35M
▲ +37.0% YoY
Net Income (TTM)
-$11M
▲ +13.8% YoY
Op. Margin
-17.99%
▲ +11.6pp YoY
ROIC
-16.10%
▲ +13.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▼ -0.7% YoY
Op. Cash Flow (TTM)
-$9M
▼ -8.1% YoY
Net Debt
-$9M
Net Cash Position
Cash & Equiv.
$23M
3Y CAGR: +84.5%
Continue Research
Is BioHarvest Sciences (BHST) overvalued?
BioHarvest Sciences (BHST)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, BioHarvest Sciences scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is BioHarvest Sciences a high-quality business?+
BioHarvest Sciences scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -18.0% operating margin and a -16.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is BioHarvest Sciences a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh BHST's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Packaged Foods
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.